Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...

Microbial infections, caused by bacteria, viruses, and parasites, pose a significant challenge to global health, affecting millions annually. Despite advancements in medical science, understanding the ...

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

An interview with integration vendor Celigo about Aura, its new conversational agent, sparks some thoughts about the future ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

"Health systems already have dedicated teams working hard to prevent readmissions," said Brad Prugh, CEO of Care Continuity. ...

Explore how landmark judgments reshape legal precedents, blending old rules with new realities and the human stories behind ...

Odd chemical pathways can give completely unexpected makeovers to some of the most troublesome waste; take, for example, an ...

Learn what the Nipah virus is, how it spreads, and why it has one of the highest fatality rates among infectious diseases.